Feng Bian
About Feng Bian
Feng Bian is the Executive Director of Integrative Sciences/China R&D at Bristol Myers Squibb, with extensive experience in the pharmaceutical industry and a strong background in biochemistry and molecular biology.
Current Role at Bristol Myers Squibb
Feng Bian serves as the Executive Director of Integrative Sciences for China R&D at Bristol Myers Squibb. In this role, he is responsible for leading scientific initiatives and research and development efforts in China. His work centers on integrating multiple scientific disciplines to drive innovation and advancement in medical research.
Previous Role at Pfizer
Before joining Bristol Myers Squibb, Feng Bian worked at Pfizer in various roles. From 2019 to 2021, he was the Senior Director and Asia Emerging Science Lead for Emerging Science & Innovation in Shanghai, China. Prior to that, he held positions as a Principal Scientist in multiple departments including Neuroscience Research Unit, Dermatology, CNS Pharmacology-Psychotherapeutics, and CNS Pharmacology-Neurodegeneration. His tenure at Pfizer spanned across different research specialties and locations including Groton, CT and Ann Arbor, MI.
Experience at Novartis and Johnson & Johnson
Feng Bian has also held significant roles at Novartis and Johnson & Johnson. At Novartis, he served as a Senior Investigator I at China Novartis Institutes for Biomedical Research from 2014 to 2019. At Johnson & Johnson, he was the Associate Director of Biology Research from 2012 to 2014 in Shanghai, China. These roles further underscore his extensive experience in scientific research and leadership in the pharmaceutical industry.
Educational Background
Feng Bian holds a Ph.D. in Biochemistry from The Ohio State University and a B.S. in Biochemistry from Nankai University. His educational background provided a strong foundation for his expertise in molecular biology and various research techniques.
Technical Expertise
Feng Bian has a broad range of technical expertise in developing animal and transgenic models, receptor autoradiography, in situ hybridization, immunohistochemistry, and histology. He is also experienced in qPCR and ELISA techniques and proficient in in vitro, ex vivo, and in vivo imaging. His skills extend to lab management, change management, outsourcing R&D projects, and stakeholder liaison and project management within the pharmaceutical industry.